BioSpace News Archive

Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the fourth quarter and full year 2022.

SaNOtize Research and Development Corp., a Canadian anti-infective-focused therapeutics company, announced the formation of its inaugural scientific advisory board, comprised of internationally renowned scientific and clinical leaders from Canada, the United States, and Europe.

Zomedica Corp. announced today that the Company will be participating in the Lytham Partners Investor Select Conference taking place virtually on January 31, 2023.

Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, today announced details of the Company’s participation at the 2023 Transdermal and Microneedle Conference taking place January 23-24, 2023, at the Copthorne Tara Hotel, London, United Kingdom.

Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 million in 2022.

Eli Lilly and Company announced plans to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company’s Research Triangle Park facility.

NanoMosaic announced the establishment of Scientific Advisory Board (SAB) to support NanoMosaic’s vision to bring the nanoneedle-powered digital proteomic tool to the life science research and the diagnostic community.

Gritstone bio, Inc. today announced that the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 28,000 shares of its common stock with an exercise price of $3.67, which is equal to the closing price of Gritstone’s common stock on January 9, 2023, the date of the grant.

Decibel Therapeutics today announced authorization of its Clinical Trial Application (CTA) by the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate.

CymaBay Therapeutics, Inc. today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.